INTRODUCTION
Angiogenesis, the formation of new blood vessels from pre-existing vessels, is not only an essential physiological process, but also a key feature of a number of pathological processes (Folkman and Klagsbrun, 1987) . Several families of mediators of angiogenesis have been described (Carmeliet and Jain, 2011; Kerbel, 2008) , but it is now well established that VEGF-A is an essential regulator of this process (Ferrara and Kerbel, 2005) . The binding of VEGF-A to its major tyrosine kinase receptor, VEGFR2, stimulates the proliferation of endothelial cells via the RAS/RAF/MEK/ERK signaling pathway (Herbert and Stainier, 2011; Olsson et al., 2006) . The critical role of the VEGF pathway is supported by genetic studies showing that the embryos of vegfa +/À mice (Carmeliet et al., 1996; Ferrara et al., 1996) and vegfr2 (flk1) À/À (Shalaby et al., 1995) mice have major defects in the development of the vasculature, resulting in embryonic lethality. In addition, the VEGF signaling pathway represents a validated therapeutic target for cancer and intraocular neovascular disorders (Ferrara and Adamis, 2016; Ferrara and Kerbel, 2005) . Multiple isoforms of VEGF-A exist. Alternative splicing of exons 6 and 7 of the VEGF gene gives rise to VEGF 121 , VEGF 165 , VEGF 189 , and VEGF 206 , the originally described isoforms (reviewed in Ferrara et al., 2003) . Subsequently, less common isoforms have been reported, including VEGF 145 and VEGF 183 (Ferrara, 2004; Neufeld et al., 1999) . A major difference among these isoforms is the affinity for heparin. VEGF 189 and VEGF 206 each have two heparin-binding domains encoded by exon 6 and 7, while VEGF 165 has only the exon-7-encoded heparin-binding domain (Ferrara et al., 2003) . VEGF 121 is devoid of significant heparin affinity (Ferrara et al., 2003) . VEGF 165 is the most frequently expressed isoform in normal tissues and in tumors (Ferrara, 2004; Neufeld et al., 1999) and has an intermediary behavior between that of the highly diffusible VEGF 121 and the strongly extracellular matrix (ECM)-bound VEGF 189 . Interaction of the heparin-binding VEGF isoforms with the coreceptor Neuropilin (NRP)-1 increases their binding affinity for VEGFR-2 and potentiates the effectiveness of signal transduction (Soker et al., 1998) . Also, the COOH terminus of VEGF 165 has cleavage sites for plasmin and matrix metalloproteinases (MMPs) (Ferrara, 2010) . These ubiquitous proteases can generate diffusible and bioactive VEGF-A fragments (Houck et al., 1992; Keyt et al., 1996; Lee et al., 2005) . Indeed, much evidence supports important roles for such proteolytic products of VEGF during angiogenesis (Ferrara, 2010) .
Over the last several years, inhibitory VEGF-A isoforms have also been reported. The first was VEGF 165b (Bates et al., 2002) , a variant with an alternative 6-amino-acid end, resulting from splicing from the end of exon 7 into the 3 0 untranslated region, thus replacing the sequences encoded by exon 8 (Bates et al., 2002) . This molecule was reported to inhibit VEGF 165 activity in multiple contexts (Bates et al., 2002; Woolard et al., 2004) , although subsequent studies have cast some doubt on such inhibitory functions and even on the existence of VEGF 165b (Harris et al., 2012) . Recently, VEGF-Ax has been described as a novel inhibitory isoform that arises from an entirely different mechanism, programmed readthrough translation (Eswarappa et al., 2014) . Compared to VEGF 165 , VEGF-Ax has a 22-aminoacid extension in the carboxyl (COOH) terminus. VEGF-Ax has been reported to have potent anti-angiogenic effects and to function as a negative regulator of VEGF signaling in endothelial cells. However, no clear mechanism for these inhibitory functions was elucidated (Eswarappa et al., 2014) . Given the potential importance of these findings, we cloned and expressed recombinant VEGF-Ax, with the aim of deciphering the inhibitory signals emanating from the C-terminal domain unique to VEGF-Ax.
RESULTS
To investigate the effects of VEGF-Ax on endothelial cells, a DNAfragment-encoding bovine (b) VEGF-A 164 with a COOH-terminal extension (Eswarappa et al., 2014) was synthetized and inserted into the vectors, generating VEGF-Ax expression plasmids as described in STAR Methods. Figure 1A illustrates the sequences of the insert. The 22-amino-acid C-terminal extension is boxed and highlighted, and a blue S indicated the canonical stop codon tga replaced by tcc (serine). The presence of untagged or Histagged (COOH terminus) VEGF-Ax in the conditioned media of transfected 293T cells was confirmed by western blot ( Figure 1B ).
We then tested the effects of the conditioned media on endothelial cell proliferation. As shown in Figure 1C , conditioned media from cells transiently expressing untagged or His-tagged VEGF-Ax unexpectedly resulted in robust, dilution-dependent stimulation of bovine choroidal endothelial cell (BCEC) proliferation (p < 0.001). Conditioned media from empty vector transfected cells had comparably little mitogenic activity. No evidence of inhibition was observed in multiple assays of independent
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(A) Sequence of VEGF-Ax. The 22-COOH-terminal extension is highlighted in the gray box, and the blue S indicates the canonical stop codon tga replaced by tcc (serine). The signal peptide is boxed.
(B) Transient expression of VEGF-Ax. 293T cells were transfected with four individual plasmids (1-4) of untagged or his-tagged VEGF-Ax and control empty vectors (pcDNA3 and pcDNA4). After 48 hr, the cell culture media were collected and subjected to immunoblot analysis by anti-VEGF or anti-His antibodies.
(C) Effects of conditioned media of transfected cells on BCECs. BCECs were cultured in the presence of different volumes of 293T cell conditioned media, as indicated in the figure. pcDNA3 and pcDNA4 denote media conditioned by cells transfected with the empty vectors; Ax-2 and Ax-3 denote media conditioned by cells transfected with untagged VEGF-Ax; His-Ax-2 and His-Ax-3 indicate media conditioned by cells expressing His-VEGF-Ax. N and V indicate, respectively, untreated and VEGF 165 (10 ng/mL) treated groups. After 6 days, cell proliferation was analyzed. Error bars represent means ± SD. The Ax-2 and Ax-3 groups were compared to the pcDNA3 group. The His-Ax-2 and His-Ax-3 groups were compared to the pcDNA4 group. V was compared to N. The experiments were carried out in triplicate and repeated more than three times. Asterisks denote significant differences compared to the appropriate control groups (***p < 0.001, **p < 0.01, *p < 0.05).
transfections. We performed most of our analyses with the untagged protein, being arguably more physiologically relevant than the His-tagged protein since it is expected to be identical to the native protein.
To purify untagged VEGF-Ax from 293T-cells-conditioned media, we performed affinity chromatography using a column coupled with anti-VEGF monoclonal antibody (mAb) B.20.4.1 . This mAb binds VEGF-A across species, and its binding epitope in VEGF-A closely corresponds to the receptor-binding epitope (Fuh et al., 2006) . Therefore, mAb B.20.4.1 should provide an unbiased capture of functional molecular forms of VEGF-Ax in the medium. As shown in Figure 2A , this method achieved purification to near homogeneity, as assessed by silver-stained gel. We detected, in the peak fractions, a major band of approximately 25 kDa in reducing conditions, consistent with the full-length VEGF-Ax monomer. This band accounted for $90% of the proteins by densitometry. A doublet of $18-20 kDa was also detectable. As shown in Figure 2A , total VEGF concentrations as determined by ELISA were strongly correlated with the intensity of the bands in the gel. We made five independent preparations of untagged VEGF-Ax, with very similar results.
For purification of His-VEGF-Ax, His-Trap R (Ni-Sepharose) columns were used and three independent purifications were performed. The recovery of purified His-VEGF-Ax, as assessed by ELISA, was comparable with that of the anti-VEGF antibody affinity column (data not shown). It is noteworthy that only His- VEGF-Ax with an intact C terminus can bind the His-Trap column, while cleaved forms devoid of His-tag would not be retained.
We performed mass spectrometry (MS) analysis to structurally characterize the purified untagged VEGF-Ax proteins. The above mentioned higher and lower molecular mass bands were cut and submitted for analysis. As shown in Figure 2B , several peptide sequences (up to 67 amino acids) were identified in both samples with over 95% confidence, and all of those peptide sequences matched the sequence of bVEGF-A 164 (Leung et al., 1989) . A partial amino-acid sequence of the C-terminal extension ''SAGLEEGASL'' was detected with over 95% confidence in the 25 kDa sample digested by trypsin. GluC digestion yielded another partial sequence of the C-terminal extension ''GASLRVSGTRRLTRKD'' with over 95% confidence, showing overlap in ''GASL.'' Therefore, the entire sequence of the 22-amino-acid extension unique to VEGF-Ax was unambiguously detected in the major protein band using this two-enzyme digestion strategy. The lower band sample was consistent with C-terminal proteolytic products of VEGF-Ax lacking the 22-amino-acid extension.
We tested purified VEGF-Ax in endothelial cell mitogenic assays. BCECs and BRECs (bovine retinal endothelial cells) were cultured in the presence of different concentrations of VEGFAx, with or without VEGF 165 . Untagged VEGF-Ax significantly (p < 0.001) induced proliferation of both BCECs ( Figure 3A ) and BRECs ( Figure 3B ) in a dose-dependent manner. The magnitude of the stimulation was 50%-70% of that obtained with VEGF 165 . Similarly, His-tagged VEGF-Ax significantly (p < 0.001) induced BCEC proliferation ( Figure 3C ). As shown in Figure S1 (related to Figure 3 ), untagged and His-tagged VEGF-Ax had a very similar ability to stimulate phosphorylation in VEGFR2 Y1175 and ERK1/2 activation. Importantly, no inhibition of VEGF 165 -stimulated endothelial cell proliferation was observed in the presence of untagged or His-tagged VEGF-Ax. To test the specificity of the effects of VEGF-Ax, we used mAb B20.4.1. Addition of mAb B20.4.1 almost completely (p < 0.001) inhibited VEGF-Ax-or VEGF 165 -induced BCEC proliferation. In contrast, a control immunoglobulin G (IgG) had no effect on BCEC proliferation stimulated by VEGF-Ax or VEGF 165 ( Figure 3D ). To determine VEGF-A release from bovine endothelial cells, we measured total VEGF-A by ELISA in the cell culture media collected at various time points ( Figure 3E ). We found that the amounts of VEGF-A were very low; the highest concentration was 25 pg/mL in BAECs (bovine aortic endothelial cells) and BCECs, and it was almost undetectable in BRECs.
Migration of human umbilical vein endothelial cells (HUVECs) was also assessed. As shown in Figure 4A , the number of migrated cells significantly (p < 0.01) increased in the presence of VEGF-Ax or VEGF 165 . In this assay, the magnitude of the effect of the two ligands was comparable. No inhibition of VEGF 165 -induced endothelial cell migration was observed when VEGFAx and VEGF 165 were combined.
To further confirm the effects of VEGF-Ax on endothelial cell proliferation and migration, BCEC monolayers were mechanically wounded. As shown in Figure 4B , in the presence of VEGF 165 , VEGF-Ax, or both, cell proliferation and migration 165 . After 5-6 days, cell proliferation was determined by fluorescence readings at 590 nm. N and V indicate, respectively, untreated and VEGF 165 (10 ng/mL) treated groups. Asterisks denote significant differences compared to control untreated groups. (D) Specificity of the effects of VEGF-Ax on BCECs. 2 mg/mL of anti-VEGF mAb B20.4.1 or isotype control IgG2a was added 1 hr before treatment with VEGF-Ax or VEGF 165 at the indicated concentrations. Asterisks denote mAb B20.4.1 groups that are significantly different from the control IgG2a groups (***p < 0.001, **p < 0.01). (E) Release of endogenous VEGF-A by bovine endothelial cells. BCECs, BRECs, and BAECs were cultured in low glucose DMEM supplemented with 2.5% bovine calf serum, and the media were collected at 24, 48, 72, and 96 hr, respectively, and concentrated 26-fold by 10k Millipore Amicon centrifugal columns prior to ELISA. All of the experiments were carried out in triplicate and repeated at least three times. Asterisks denote groups that are significantly different from the control medium (no cells) groups (***p < 0.001, **p < 0.01, *p < 0.05).
toward the gap between the wound edges were evident, resulting in a significantly narrower gap compared to the control group. There was no evidence that VEGF-Ax antagonized the activity of VEGF 165 .
Explanted mouse choroidal tissue provides a model for studying microvascular proliferation (Shao et al., 2013) . We used this assay to evaluate the pro-angiogenic effect of VEGF 165 , VEGF-Ax, and these molecules in combination.
In pilot experiments, we tested various concentrations of VEGF 165 and identified 25 ng as a concentration that strongly stimulates vessel sprouting relative to buffer control. When compared to 25 ng of VEGF-Ax, an equivalent amount of vessel proliferation over the same time period was observed. No difference in the density or extent of vessel proliferation was identified ( Figure 5A ). Furthermore, increasing the concentrations of VEGF-Ax or combining with lower concentration of VEGF 165 did not induce further stimulation (or inhibition) of vessel proliferation. These data suggest very similar effects of VEGF 165 and VEGF-Ax on choroidal explant vascular proliferation.
One of the known activities of VEGF is the rapid induction of vascular permeability from an intact endothelium (Senger et al., 1983 ). Therefore, we tested the ability of VEGF-Ax to induce vascular permeability in the Miles assay. As shown in Figure 5B , VEGF-Ax induced dye extravasation in a dose-dependent manner The experiments were carried out in triplicate, and the error bars represent means ± SD from three independent experiments. (B) Migration and proliferation analyzed by scratch assay. Subconfluent BCEC monolayers in 6-well plates were serum starved and wounded, followed by addition of 50 ng/mL VEGF-Ax, 50 ng/mL VEGF 165 , or a combination of both ligands, each at 50 ng/mL in duplicate wells. 48 hr later, images were acquired by ZEISS Discovery V8 SteREO microscope equipped with PixeLINK Megapixel FireWire camera. Quantification of wound closure was done using AxioVision LE Rel.4.4 software. Six measurements were taken of each image, and values are means ± SD from four independent studies. Asterisks denote significant differences compared to no addition (N/A) groups (***p < 0.001, **p < 0.01).
compared to PBS control (dose 0). VEGF 165 , as expected, strongly induced dye leakage. Administration of 50 ng of VEGF 165 combined with different doses of VEGF-Ax (25-250ng) induced more dye extravasation compared to VEGF 165 or VEGF-Ax treatment alone.
After this work was essentially completed, human VEGF-Ax became available from R&D Systems. As shown in Figure 6 , R&D Systems VEGF-Ax and our purified VEGF-Ax had comparable mitogenic effects on bovine endothelial cells and did not inhibit VEGF 165 -stimulated proliferation, even at a molar ratio of $10:1. We also tested, in the same assay, VEGF 165b , which also stimulated endothelial cell proliferation and did not inhibit VEGF 165 -stimulated growth (Figure 6 ).
Given the finding that VEGF-Ax has both mitogenic and permeabilizing effects, we examined the phosphorylation status of two key tyrosine residues in VEGFR2, Y1175 and Y951, which have been implicated, respectively, in the induction of endothelial cell proliferation (Sakurai et al., 2005) and of vascular permeability (Li et al., 2016) . As shown in Figure 7A , VEGF-Ax purified in our laboratory or VEGF-Ax purchased from R&D Systems induced phosphorylation of both Y1175 and Y951 in VEGFR2. VEGF 165b also induced phosphorylation of both tyrosine residues ( Figure 7A ). Since p44/42 MAPK (ERK1/2) is downstream of VEGFR2 activation, we also tested the phosphorylation status of ERK1/2. In agreement with the VEGFR2 tyrosine phosphorylation data, VEGF-Ax, VEGF 165 , and, to a lesser extent, VEGF 165b stimulated p-ERK1/2 ( Figure 7A ).
Using an ELISA-based approach, we sought to determine whether VEGF-Ax is able to compete with biotinylated VEGF 165 for NRP1 binding. Unlike VEGF 165 , neither VEGF 121 nor VEGF-Ax significantly competed with biotinylated VEGF 165 ( Figure 7B ).
DISCUSSION
By alternative mRNA splicing, multiple VEGF-A isoforms are generated, including VEGF 121 , VEGF 165 , and VEGF 189. (Houck et al., 1991; Tischer et al., 1991) These isoforms have been characterized as having pro-angiogenic functions in vitro and in vivo, although the degrees of potency varied depending on the C-terminal sequences and the ability to bind NRP1 (Carmeliet et al., 1999; Houck et al., 1992; Keyt et al., 1996; Soker et al., 1998) .
In 2002, Bates et al. (2002) reported the existence of an additional isoform, VEGF 165b , which was reported to have paradoxically anti-angiogenic effects and the ability to antagonize VEGF-A-induced effects (Bates et al., 2002) . Potentially, this study provided a new paradigm of VEGF-A regulation and function. However, these findings have not been without controversy, as some groups were unable to confirm antagonistic properties of VEGF 165b and, instead, reported weak agonistic activities (Catena et al., 2010; Kawamura et al., 2008) . In the present study, we also found that VEGF 165b has mitogenic effects on endothelial cells.
Recently, Eswarappa et al. (2014) have described a novel anti-angiogenic VEGF-A isoform, VEGF-Ax, resulting from programmed readthrough translation. VEGF-Ax includes a 22-amino-acid C-terminal extension due to reading of the canonical stop codon as a serine. Readthrough translation, which occurs primarily in viruses and fungi but has been observed also in mammals, consists of decoding a canonical stop codon as a sense codon due to the pairing of a near-cognate aminoacyltRNA to the stop codon in the ribosomal A site instead of eRF1 (Beier and Grimm, 2001; Firth and Brierley, 2012; Namy et al., 2004) . This process results in the generation of C-extended proteins, thus potentially enhancing functional diversity and even affecting cellular localization (Schueren et al., 2014) . It is generally agreed that such C-terminally extended proteins represent low-abundance products that account for a small fraction of the translated proteins in mammals (Schueren et al., 2014) .
Intriguingly, VEGF-Ax was characterized as an antagonist and proposed to function as an endogenous inhibitor of VEGF-mediated angiogenesis (Eswarappa et al., 2014) . However, an initial analysis of the 22-amino-acid extension unique to VEGF-Ax does not reveal any known domain or motif that might account for such inhibitory effects. Four out of 22 residues are hydrophobic, and 7 out of 22 are charged. Therefore, this extension might potentially bind to heparin.
The authors suggested that the reported inhibitory effects are related to the inability of VEGF-Ax to bind NRP1 (Eswarappa et al., 2014) . Indeed, we have been able to confirm that VEGFAx has a markedly reduced if not undetectable ability to compete with VEGF 165 for NRP1 binding. This finding is somewhat surprising, considering that, unlike VEGF 165b (Kawamura et al., 
. Effects of VEGF Variants on Bovine Choroidal Endothelial Cell Proliferation
Different concentrations of VEGF-Ax purified in our laboratory (UCSD) or VEGF-Ax from R&D Systems were tested in the presence or absence of 10 ng/mL VEGF 165 . VEGF 165b was also tested under similar conditions. The experiments were carried out in triplicate and repeated three times. Data shown are means ± SD. Asterisks denote significant differences compared to no treatment (0) groups (***p < 0.001, **p < 0.01, *p < 0.05).
Figure 7. VEGF-Ax Induces VEGFR2 Signaling and Fails to Bind NRP1
(A) Western blot showing increased phosphorylation of VEGFR2 Y1175 and Y951 and ERK1/2 activation induced by VEGF-A variants. Serum-starved HUVECs were stimulated for 10 minutes with 50 ng/mL of VEGF-Ax purified in our laboratory (UCSD), commercial VEGF-Ax (R&D), VEGF 165b , or wild-type VEGF 165 . Each VEGF variant was compared to its appropriate vehicle control. N/A, no addition. Equal amounts of whole-cell lysates were subjected to SDS-PAGE and then blotted with the indicated antibodies. (B) Solid-phase NRP1 binding assay. VEGF 165 , but not VEGF-Ax or VEGF 121 , is able to compete with biotinylated VEGF 165 for binding to NRP1-Fc. The assays were carried out in duplicate wells. The values shown are means ± SD from three independent studies. Asterisks denote significant differences compared with control buffer (***p < 0.001, *p < 0.05).
2008), VEGF-Ax has all the structural elements required to bind NRP1 (Vander Kooi et al., 2007) . It is generally accepted that the C-terminal exon-8-encoded sequences in VEGF represent the site of direct interaction between VEGF 165 and NRP1, although sequences encoded by exon 7 are required to extend this region to effectively gain access to the NRP1 dimer (Vander Kooi et al., 2007) . Thus, it appears that the 22-amino-acid extension in VEGF-Ax blocks or disrupts this interaction. Structural studies will be required to define these blocking effects. However, the hypothesis that loss of NRP1 binding confers antagonistic or inhibitory properties lacks structural basis. Indeed, VEGF 121 (which lacks exon-7-encoded sequences), C-terminal proteolytic fragments of VEGF 165 resulting from plasmin (Houck et al., 1992; Keyt et al., 1996) , or matrix metalloproteinase (MMP)3 (Lee et al., 2005) cleavage and VEGF mutants (Li et al., 2000) lacking all exon-7-and exon-8-encoded sequences have reduced or absent ability to bind NRP1 (Soker et al., 1998; Vander Kooi et al., 2007) . Nevertheless, all of these variants have been shown to induce VEGFR2 phosphorylation, mitogenesis, angiogenesis, and vascular permeability, albeit with reduced potency compared to intact VEGF 165 (Houck et al., 1992; Keyt et al., 1996; Lee et al., 2005; Li et al., 2000; Park et al., 1993) .
To gain some mechanistic insights into the reported antiangiogenic effects of VEGF-Ax, we cloned and expressed both untagged and His-tagged VEGF-Ax and purified the recombinant proteins. We were able to document by MS of the untagged protein, purified by affinity chromatography using an anti-VEGF function-blocking antibody, that the major VEGF-Ax band has an intact 22-amino-acid extension. A much-less-abundant molecular form was consistent with proteolysis of VEGF-Ax at the C terminus, a well-known feature of the VEGF proteins in vitro and in vivo (Ferrara, 2010) . Therefore, it is likely that the VEGF-Ax purified by this approach more closely reflects the heterogeneity occurring in the microenvironment, as compared to His-VEGF-Ax purified by His-Trap columns, since an intact C terminus is required to bind the column in this case. Nevertheless, purified untagged and His-tagged VEGF-Ax proteins had very similar mitogenic effects and abilities to induce VEGFR2 tyrosine phosphorylation and ERK1/2 activation.
In contrast with the findings by Eswarappa et al. (2014) , we were unable to detect any inhibition of either basal or VEGF-stimulated endothelial cell growth even with a VEGF-Ax/ VEGF 165 $10:1 molar ratio. Using a variety of in vitro, ex vivo, and in vivo bioassays, we documented clear agonistic activities of VEGF-Ax. Importantly, these effects were observed across a broad spectrum of experimental conditions, ranging from 10% serum to serum-free conditions. In agreement with these findings, VEGF-Ax induced phosphorylation of two key VEGFR2 tyrosine residues, Y951 and Y1175.
The finding that the potency of VEGF-Ax was lower than that of VEGF 165 is entirely consistent with impaired NRP1 binding. Indeed, several studies have shown that NRP1 forms complexes with VEGF 165 , which enhance its binding affinity for VEGFR2 (Neufeld et al., 2002; Soker et al., 1998 Soker et al., , 2002 Whitaker et al., 2001) . Accordingly, as already noted, VEGF-A isoforms or proteolytic fragments of VEGF-A devoid of NRP1 binding have reduced biological potency (Houck et al., 1992; Keyt et al., 1996; Lee et al., 2005; Li et al., 2000; Park et al., 1993) . Eswarappa et al. (2014) concluded, on the basis of western blots, that VEGF-Ax is abundantly released in the supernatants of cultured bovine endothelial cells. The authors speculated that VEGF-Ax is responsible for preventing growth and maintaining endothelial cells in a quiescent state. However, using an ELISA, we found that the total amounts of VEGF-A released by three different bovine endothelial cell types are exceedingly low or undetectable, raising the question of whether such amounts may even be biologically significant. Specific and quantitative methodologies are clearly needed to accurately estimate the concentrations of VEGF-Ax in endothelial cells and in other cell types, in vitro and in vivo.
How can we account for the conflicting findings? One could speculate that the inhibitory function of VEGF-Ax associated with the C terminus might have been impaired or disrupted in the course of the purification procedures employed by us. However, the finding that the starting material, the unprocessed conditioned media of transfected cells expressing untagged or His-tagged VEGF-Ax, consistently induced endothelial cell proliferation clearly argues against the hypothesis. Importantly, the commercially available VEGF-Ax had similar mitogenic effects to the proteins prepared in our laboratory. An alternative possibility is that the reported inhibitory effects (Eswarappa et al., 2014) may be mediated by contaminants or impurities. In this context, when screening a library of human secreted proteins (Clark et al., 2003) to identify growth stimulators and inhibitors for bovine endothelial cells ), we observed a surprisingly high rate of inhibitory ''hits'' using an early version of the library. Most of these ''hits'' were not confirmed with more stringently purified proteins. It became apparent that endothelial cell growth could be easily inhibited by a variety of impurities, including protein aggregates or traces of imidazole, a buffer typically used to elute His-tagged proteins from Ni-Sepharose columns. It remains to be established whether any of these possibilities account for the conflicting results.
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EXPERIMENTAL MODELS AND SUBJECT DETAILS Mice
Twenty-five healthy, naive wild-type C57BL/6J mice were used for mouse choroidal explant assays. Mice (male, age P20) were purchased from Jackson Laboratories and were used on the day of arrival. Animals were housed in clean cages and experimental procedures were carried out under pathogen-free conditions in accordance with established standards of care and approved protocols from the Animal Care and Use Committee of the University of California, San Diego. Prior to tissue harvest, mice were euthanized by CO 2 inhalation followed by cervical dislocation.
Guinea Pigs
Five healthy naive hairless guinea pigs were used for vascular permeability assay. Guinea pigs (Crl: HA-Hrhr/IAF, male, 450-500 g, approximately 2 months old), were purchased from Charles River Laboratories. Animals were individually caged and maintained in pathogen-free conditions in accordance with related guidance and approved protocols from the Animal Care and Use Committee of the University of California, San Diego.
Cells
Human 293T cells were maintained in high glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Primary human umbilical vein endothelial cells (HUVEC, passage 4-10, were cultured on 0.1% gelatin-coated plates in EGM-2 endothelial cell growth media. Bovine retinal microvascular endothelial cells (BRECs) and bovine choroidal microvascular endothelial cells (BCECs) were maintained in fibronectin-coated plates (1 mg/cm 2 ). The growth medium was low glucose DMEM supplemented with 10% bovine calf serum, 5 ng/ml bFGF and 10ng/ml hVEGF 165 . Bovine aortic endothelial cells were cultured in high glucose DMEM supplemented with 5% fetal bovine serum. Cells were maintained at 37 C in a humidified atmosphere with 5% CO 2 .
METHOD DETAILS Plasmid Construction and Transfection
For construction of VEGF-Ax expression plasmids, a 639-bp nucleic acid fragment of bovine (b) VEGF-A 164 and a 22-aminal acid C-terminal extension, in which the canonical stop codon tga was replaced by tcc (serine) (Eswarappa et al., 2014) , was synthesized (GenScript USA Inc.) and inserted into pcDNA3 or pcDNA4(A)/myc-His vectors at HindIII/BamHI and Hind III/AgeI sites, generating respectively pcDNA3-VEGF-Ax and pcDNA4-His-VEGF-Ax plasmids. 293T cells were used for transient expression. Transfections were carried out using Lipofectamine 3000 according to the instructions of the manufacturer. The authenticity of all constructs was verified by sequence analysis.
Conditioned Media Preparation and VEGF-A ELISA
Three million 293T cells in 10 cm-dishes were transfected as above described. After 6 hr, cells were washed three times with PBS followed by incubation with 10 ml of serum free medium (FreeStyle 293 expression medium). After 72 hr, media were collected. Aliquots were tested for bioactivity and the bulk was concentrated ten-fold by 10k Amicon centrifugal columns (EMD Millipore) and stored at À80 C until further use. Total VEGF concentrations were measured using a bovine VEGF-A ELISA kit, according to the manufacturer's instructions.
Western Blots
To detect expression of VEGF variants, 25 mL aliquots of conditioned media from 293T cells transiently expressing VEGF-Ax, His-VEGF-Ax or from empty vector-transfected cells, were collected and mixed with NuPAGEâ LDS Sample Buffer (4X). The samples were subjected to SDS-PAGE and blotted with anti-VEGF (A-20) or 6x-His Epitope Tag Antibody. To determine phosphorylation of VEGFR2 (tyrosine 951 or 1175) and ERK1/2, HUVECs (passage 6-8) were plated in EBM-2 basal medium with 0.2% FBS. Following overnight culture, cells were serum-starved in EBM-2 medium for 4 hr prior to treatment with 50 ng/ml of VEGF variants or vehicle controls for 10 min. Equal amounts of whole-cell lysates were analyzed by SDS-PAGE and blotted with the indicated antibodies.
Bovine Endothelial Cell Proliferation Assays
Proliferation assays were performed essentially as previously described (Yu et al., 2008) . BCECs and BRECs were seeded in 96-well plates (no coating) in low glucose DMEM supplemented with 10% bovine CS, 2 mM glutamine, and antibiotics (growth medium), at a density of 1000 cells per well in 200 ml volume. VEGF-Ax or VEGF 165 was added at the indicated final concentrations. For VEGF neutralization, 2 mg/ml of anti-VEGF mAb B20.4.1 or isotype control IgG2a was first added to triplicate wells. One hour later, VEGF-Ax or wild-type VEGF 165 was added at the indicated concentrations. After 5 or 6 days, cells were incubated with Alamar Blue for 4h. Fluorescence was measured at 530 nm excitation wavelength and 590 nm emission wavelength. The experiments were repeated at least three times.
VEGF Release from Cultured Bovine Endothelial Cells
To assess total VEGF-A release by cultured bovine endothelial cells, BCECs, BRECs and BAECs ($2 million cells) were plated into 60-mm dishes (1 mg/cm 2 fibronectin -coated plates for BCECs and BRECs) in low glucose DMEM supplemented with 10% calf serum with 5 ng/ml bFGF and allowed cells grow to 80% confluency. Cells were then washed three times with PBS and incubated with 4 ml of low glucose DMEM supplemented with 2.5% bovine calf serum. Media were collected at 24, 48, 72 and 96h respectively. Media were concentrated 26-fold by 10k Millipore Amicon centrifugal columns prior to ELISA.
HUVEC Migration Assay
HUVECs (passage 6-8) were cultured and serum-starved as described in ''Western blots.'' The cells (10000 cells) in 150 ml of EBM-2 medium were then added to the upper chamber of 8 mm pore size cell culture inserts (Falcon) coated with 0.1% gelatin. The lower compartment was filled with 600 ml EBM-2 medium containing 20 ng/ml VEGF 165 , 50 ng/ml VEGF-Ax or 20 ng/ml VEGF 165 plus 50 ng/ml VEGF-Ax. The plates were incubated at 37 C to allow migration. After 4h, cells were fixed with 4% PFA for 20 min and then stained with crystal violet for 20 min at RT. Migrated cells on the bottom side of the insert membrane were quantified by counting whole area of the insert at 40X magnification. The experiments were carried out in triplicate and repeated three times.
Scratch Assay
BCECs (passage 6-10) were used in the assay. Cells were cultured in growth medium in 6-well plates until about 80% confluent. They were then washed twice with PBS and incubated in serum-free DMEM for 5 hr before making an incision in the cell monolayers using a 1 ml pipette tip. Cells were washed once with serum-free media, followed by addition of media containing 1% FBS and test molecules. After 48 hr, the assay was stopped by adding 2 ml 4% paraformaldehyde. Twenty minutes later, the fixed cells were stained with 1ml Crystal Violet. Plates were washed gently with water and then air-dried before taking pictures. Images were acquired by ZEISS Discovery V8 SteREO microscopy equipped with PixeLINK Megapixel FireWire camera. Quantification of wound closure was accomplished using AxioVision LE Rel.4.4 software. Six measurements were taken on each field.
Mouse Choroidal Explant Assay
Using pre-cooled pipette tips, 130 ml of reduced growth factor basement membrane extract (BME) was added to each well in a 48-well plate. To avoid evaporation, surrounding wells were filled with PBS. BME was allowed to solidify at 37 C for 20 min. One peripheral sclerochoroidal wedge, dissected from male C57BL/6J (age P20) mice, was added to the center of each well, as previously described (Shao et al., 2013) ; care was taken to disrupt the tissue minimally. Each experimental condition was tested from explants from a single eye, and was repeated five times. The tissue was incubated at 37 C for 15 min prior to the addition of a top layer of 130 ml BME. After a 30 min incubation period, 500 ml of growth media was added to each well (human endothelial serum free-media containing 2% FBS, 50 units/ml penicillin and 50 mg/ml streptomycin), plus varying concentrations of VEGF 165 and VEGF-Ax. Explants were incubated in standard cell culture conditions with 5% CO 2. Fresh media was exchanged at day 2 and day 4. Images were taken on day 4 and day 6 using an inverted microscope with a 10X objective and acquired using Axiovision software.
Vascular Permeability Assay
Vascular permeability was assessed using a modified Miles assay (Gille et al., 2001) . Hairless male guinea pigs (Crl: HA-Hr hr /IAF, 450-500 g, Charles River Laboratories) were anesthetized by intraperitoneal (i.p.) administration of xylazine (5 mg/kg) and ketamine (75 mg/kg). The animals then received an intravenous injection (penile vein) of 1 ml of 1% Evans blue dye. After $15 min, intradermal injections (0.05 ml/per site) of different doses (0, 25, 50, 100, 250 ng per injection site) of VEGF-Ax, VEGF 165 and a combination of 50 ng VEGF 165 with different doses of VEGF-Ax (0, 25, 50, 100, 250 ng) were administrated into the area of trunk posterior to the shoulder. VEGF-Ax and VEGF 165 were diluted in PBS for intradermal administration. 1.5 mg per site of histamine was used as positive control. 30 min after the intradermal injections, animals were euthanized by i.p. injection of pentobarbital (200 mg/kg). Skin tissues were dissected from the connective tissues and photographed. Quantification of the dye extravasation area was carried out on the pictures using ImageJ image analysis software. For each dose, measurements were made in total five animals.
Purification of VEGF-Ax
Untagged VEGF-Ax was purified from conditioned media of 293T cells transiently expressing pcDNA3-VEGF-Ax plasmid using an anti-VEGF antibody column. The column was prepared using the Pierce Protein G IgG Plus Orientation Kit according to the manufacturer's instructions. Briefly, 16 mg of anti-VEGF-A mAb B20.4.1 ) (Genentech Inc, South San Francisco, CA) was used to bind 2 ml Protein G agarose and cross-linked by treatment with DSS. The resin was then packed into a GE Healthcare Tricorn 10/50 Column. Up to 300 mg VEGF-Ax by ELISA were loaded and purified using a GE AKTA Explorer System. After loading, the column was stepwise washed with 20 mM Tris pH 7.2, containing 0.15 and 0.6 M NaCl and eluted with 0.1 M glycine,HCl, pH 2.8, which was immediately neutralized with 1M Tris,HCl, pH 9.5. His-VEGF-Ax was purified from conditioned media of 293T cells transiently expressing pcDNA4-His-VEGF-Ax plasmid by HisTrap HP columns (1ml or 5ml) (GE Healthcare). Conditioned media were exchanged into binding buffer (20 mM NaH 2 PO 4 , 0.5 M NaCl, 20 mM imidazole). After stepwise washing with 50 and 100 mM imidazole, VEGF-Ax was eluted with 20 mM NaH 2 PO 4 , 500 mM NaCl, 500 mM imidazole. Buffers was exchanged into PBS by PD-10 columns (GE Healthcare). VEGF-Ax concentrations in the fractions were measured by ELISA and the purity of the proteins were assessed by silver-stained SDS-PAGE.
Structural Analysis
For in-gel digest and mass spectrometry (MS) analysis (Shevchenko et al., 1996) , 3 mg of purified untagged VEGF-Ax were subjected to SDS-PAGE and silver-stained using a MS-compatible kit (Silverquest, Fisher Scientific). Two bands in reducing conditions, the major of about 25 kDa and the minor, a doublet of $18-20kDa, were cut from the gel and destained. The samples were separately subjected to digestion with trypsin and GluC and analyzed as described below.
In Gel Digest
The gel slices were cut to 1mm by 1mm cubes and destained 3 times by first washing with 100 ml of 100 mM ammonium bicarbonate for 15 min, followed by addition of the same volume of acetonitrile (ACN) for 15 min. The supernatant was removed and samples were dried in a speedvac. Samples were then reduced by mixing with 200 ml of 100 mM ammonium bicarbonate-10 mM DTT and incubated at 56 C for 30 min. The liquid was removed and 200 ml of 100mM ammonium bicarbonate-55 mM iodoacetamide was added to gel pieces and incubated at room temperature in the dark for 20 min. After the removal of the supernatant and one wash with 100mM ammonium bicarbonate for 15 min, same volume of ACN was added to dehydrate the gel pieces. The solution was then removed and samples were dried in a speedvac. For digestion, enough solution of ice-cold trypsin (0.01 mg/ml) in 50 mM ammonium bicarbonate or
